New insights into acquired endocrine resistance of breast cancer

Abstract

The translational research strategy of targeting estrogen receptor α (ERα) positive breast cancer and then using long term anti-hormone adjuvant therapy (5-10 years) has reduced recurrences and mortality. However, resistance continues to occur and improvements are required to build on the success of tamoxifen and aromatase inhibitors (AIs) established over the past 40 years. Further translational research has described the evolution of acquired resistance of breast cancer cell lines to long term estrogen deprivation that parallels clinical experience over years. Additionally, recent reports have identified mutations in the ERα obtained from the recurrences of AI treated patients. These mutations allow the ERα to activate without ligands and auto stimulate metastatic tumor growth. Furthermore, the new biology of estrogen-induced apoptosis in acquired resistant models in vitro and in vivo has been interrogated and applied to clinical trials. Inflammation and stress are emerging concepts occurring in the process of acquired resistance and estrogen-induced apoptosis with different mechanisms. In this review, we will present progress in the understanding of acquired resistance, focus on stress and inflammatory responses in the development of acquired resistance, and consider approaches to create new treatments to improve the treatment of breast cancer with endocrine resistance.

Keywords

Estrogen receptor α / endocrine resistance / endoplasmic reticulum stress / estrogen-induced apoptosis / breast cancer

References

[1] Jordan VC.Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer..Steroids2007;72:7-25 PMCID:PMC2566956

[2] Jensen EV.The estrogen receptor: a model for molecular medicine..Clin Cancer Res2003;9:1980-9

[3] Jordan VC.Selective estrogen receptor modulation: concept and consequences in cancer..Cancer Cell2004;5:207-13

[4] Davies C,Godwin J,Arriagada R.Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial..Lancet2013;381:805-16 PMCID:PMC3596060

[5] Pan H,Braybrooke J,Taylor C.20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years..N Engl J Med2017;377:1836-46 PMCID:PMC5734609

[6] Goss PE,Pritchard KI,Muss H.Extending aromatase-inhibitor adjuvant therapy to 10 years..N Engl J Med2016;375:209-19 PMCID:PMC5024713

[7] Mamounas EP,Lembersky BC,Geyer CE Jr.Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial..Lancet Oncol2019;20:88-99

[8] Jordan VC.Selective estrogen-receptor modulators and antihormonal resistance in breast cancer..J Clin Oncol2007;25:5815-24

[9] Musgrove EA.Biological determinants of endocrine resistance in breast cancer..Nat Rev Cancer2009;9:631-43

[10] Brauch H.Prediction of tamoxifen outcome by genetic variation of CYP2D6 in post-menopausal women with early breast cancer..Br J Clin Pharmacol2014;77:695-703 PMCID:PMC3971985

[11] Fan P.Acquired resistance to selective estrogen receptor modulators (SERMs) in clinical practice (tamoxifen & raloxifene) by selection pressure in breast cancer cell populations..Steroids2014;90:44-52 PMCID:PMC4192097

[12] Shou J,Osborne CK,Ali S.Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer..J Natl Cancer Inst2004;96:926-35

[13] Sabnis GJ,Long B.The role of growth factor receptor pathways in human breast cancer cells adapted to long-term estrogen deprivation..Cancer Res2005;65:3903-10

[14] Martin LA,Weigel MT,Dunbier A.An in vitro model showing adaptation to long-term oestrogen deprivation highlights the clinical potential for targeting kinase pathways in combination with aromatase inhibition..Steroids2011;76:772-6

[15] Osborne CK,Hopp TA,Hilsenbeck SG.Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer..J Natl Cancer Inst2003;95:353-61

[16] Jordan VC,Maximov PY.Estrogen receptor mutations found in breast cancer metastases integrated with the molecular pharmacology of selective ER modulators..J Natl Cancer Inst2015;107:djv075 PMCID:PMC6390275

[17] Frasor J,Stender JD.NF-κB affects estrogen receptor expression and activity in breast cancer through multiple mechanisms..Mol Cell Endocrinol2015;418:235-9 PMCID:PMC4402093

[18] Fan P,Agboke FA,Pokharel N.Modulation of nuclear factor-kappa B activation by the endoplasmic reticulum stress sensor PERK to mediate estrogen-induced apoptosis in breast cancer cells..Cell Death Discov2018;4:15

[19] Hanahan D.Hallmarks of cancer: the next generation..Cell2011;144:646-74

[20] Grivennikov SI,Karin M.Immunity, inflammation, and cancer..Cell2010;140:883-99 PMCID:PMC2866629

[21] Murray JI,Murphy LC.Intratumoural inflammation and endocrine resistance in breast cancer..Endocr Relat Cancer2015;22:R51-67

[22] Fan P.How PERK kinase conveys stress signals to nuclear factor-κB to mediate estrogen-induced apoptosis in breast cancer cells?.Cell Death Dis2018;9:842 PMCID:PMC6089992

[23] Fan P,Chai TS,Jordan VC.Targeting peroxisome proliferator-activated receptor γ to increase estrogen-induced apoptosis in estrogen-deprived breast cancer cells..Mol Cancer Ther2018;17:2732-45 PMCID:PMC6279501

[24] Song RX,Naftolin F,Song J.Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17 beta-estradiol..J Natl Cancer Inst2001;93:1714-23

[25] Lewis JS,Osipo C,Kidawi N.Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation..J Natl Cancer Inst2005;97:1746-59

[26] Yao K,Bentrem DJ,Schafer JI.Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice..Clin Cancer Res2000;6:2028-36

[27] Liu H,Gajdos C,Chen B.Apoptotic action of 17beta-estradiol in raloxifene-resistant MCF-7 cells in vitro and in vivo..J Natl Cancer Inst2003;95:1586-97

[28] Jordan VC.The new biology of estrogen-induced apoptosis applied to treat and prevent breast cancer..Endocr Relat Cancer2015;22:R1-31 PMCID:PMC4494663

[29] Ellis MJ,Dehdashti F,Marcom PK.Lower-dose vs. high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study..JAMA2009;302:774-80 PMCID:PMC3460383

[30] Fan P,Santen RJ.Long-term treatment with tamoxifen facilitates translocation of estrogen receptor alpha out of the nucleus and enhances its interaction with EGFR in MCF-7 breast cancer cells..Cancer Res2007;67:1352-60

[31] Britton DJ,Knowlden JM,Giles M.Bidirectional cross talk between ERalpha and EGFR signaling pathways regulates tamoxifen-resistant growth..Breast Cancer Res Treat2006;96:131-46

[32] Fan P,Cunliffe HE,Jordan VC.A molecular model for the mechanism of acquired tamoxifen resistance in breast cancer..Eur J Cancer2014;50:2866-76 PMCID:PMC4194144

[33] Becker MA,Cui X,Yee D.The IGF pathway regulates ERα through a S6K1-dependent mechanism in breast cancer cells..Mol Endocrinol2011;25:516-28 PMCID:PMC3045742

[34] Osborne CK,Dirix LY,Robert J.Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study..Clin Cancer Res2011;17:1147-59 PMCID:PMC3074404

[35] Verma S,Gianni L,Welslau M.Trastuzumab emtansine for HER2-positive advanced breast cancer..N Engl J Med2012;367:1783-91 PMCID:PMC5125250

[36] Kato S,Masuhiro Y,Uchiyama S.Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase..Science1995;270:1491-4

[37] Li SY,Grieu F.PIK3CA mutations in breast cancer are associated with poor outcome..Breast Cancer Res Treat2006;96:91-5

[38] Miller TW,Gonzalez-Angulo AM,Mills GB.Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer..J Clin Invest2010;120:2406-13 PMCID:PMC2898598

[39] Szijgyarto Z,Opdam M,Linn SC.Dissecting the predictive value of MAPK/AKT/estrogen-receptor phosphorylation axis in primary breast cancer to treatment response for tamoxifen over exemestane: a Translational Report of the Intergroup Exemestane Study (IES)-PathIES..Breast Cancer Res Treat2019;175:149-63 PMCID:PMC6491661

[40] Hiscox S,Green TP,Gee J.Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells..Breast Cancer Res Treat2006;97:263-74

[41] Zhao Y.Mislocalizaion of cell-cell adhesion complexes in tamoxifen-resistant breast cancer cells with elevated c-Src tyrosine kinase activity..Cancer Lett2009;275:204-12

[42] Hiscox S,Smith C,Morgan L.Dual targeting of SRC and ER prevents acquired antihormone resistance in breast cancer cells..Breast Cancer Res Treat2009;115:57-67

[43] Fan P,Griffith OL,Ramos P.Identification of gene regulation patterns underlying both oestrogen- and tamoxifen-stimulated cell growth through global gene expression profiling in breast cancer cells..Eur J Cancer2014;50:2877-86 PMCID:PMC4210771

[44] Gottardis MM.Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration..Cancer Res1988;48:5183-7

[45] Gottardis MM,Jeng MH.Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens..Cancer Res1989;49:4090-3

[46] Fan P,McDaniel RE,Zou X.Inhibition of c-Src blocks oestrogen-induced apoptosis and restores oestrogen-stimulated growth in long-term oestrogen-deprived breast cancer cells..Eur J Cancer2014;50:457-68 PMCID:PMC3947251

[47] Osipo C,Cheng D,Bertucci A.Role for HER2/neu and HER3 in fulvestrant-resistant breast cancer..Int J Oncol2007;30:509-20

[48] Hutcheson IR,Madden TA,Gee JM.Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells..Breast Cancer Res Treat2003;81:81-93

[49] Massarweh S,Creighton CJ,Tsimelzon A.Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function..Cancer Res2008;68:826-33

[50] Fagan DH,Sachdev D.Acquired resistance to tamoxifen is associated with loss of the type I insulin-like growth factor receptor: implications for breast cancer treatment..Cancer Res2012;72:3372-80 PMCID:PMC4520534

[51] Malorni L,Migliaccio I,Creighton CJ.Blockade of AP-1 potentiates endocrine therapy and overcomes resistance..Mol Cancer Res2016;14:470-81 PMCID:PMC4867274

[52] Zhou Y,Gray JW,Dairkee SH.Enhanced NF kappa B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer..BMC Cancer2007;7:59 PMCID:PMC1852565

[53] Schiff R,Ahotupa M,Grim M.Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo..J Natl Cancer Inst2000;92:1926-34

[54] Johnston SR,Scott GK,Smith IE.Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance..Clin Cancer Res1999;5:251-6

[55] Shaulian E.AP-1 as a regulator of cell life and death..Nat Cell Biol2002;4:E131-36

[56] Aesoy R,Norum JH,Viktorsson K.An autocrine VEGF/VEGFR2 and p38 signaling loop confers resistance to 4-hydroxytamoxifen in MCF-7 breast cancer cells..Mol Cancer Res2008;6:1630-8

[57] Fan P,Maximov PY,McDaniel RE.Integration of downstream signals of insulin-like growth factor-1 receptor by endoplasmic reticulum stress for estrogen-induced growth or apoptosis in breast cancer cells..Mol Cancer Res2015;13:1367-76 PMCID:PMC4763612

[58] Harrod A,Nguyen VTM,Ramos-Garcia L.Genomic modelling of the ESR1 Y537S mutation for evaluating function and new therapeutic approaches for metastatic breast cancer..Oncogene2017;36:2286-96 PMCID:PMC5245767

[59] Cancer Genome Atlas NetworkComprehensive molecular portraits of human breast tumours..Nature2012;490:61-70 PMCID:PMC3465532

[60] Wang P,Gyanchandani R,Hartmaier RJ.Sensitive detection of mono- and polyclonal ESR1 mutations in primary tumors, metastatic lesions and cell free DNA of breast cancer patients..Clin Cancer Res2015;22:1130-7 PMCID:PMC4775406

[61] Martin LA,Simigdala N,Pancholi S.Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance..Nat Commun2017;8:1865 PMCID:PMC5709387

[62] Robinson DR,Vats P,Lonigro RJ.Activating ESR1 mutations in hormone-resistant metastatic breast cancer..Nat Genet2013;45:1446-51 PMCID:PMC4009946

[63] Toy W,Won H,Sakr RA.ESR1 ligand-binding domain mutations in hormone-resistant breast cancer..Nat Genet2013;45:1439-45 PMCID:PMC3903423

[64] Catherino WH,Jordan VC.A naturally occurring estrogen receptor mutation results in increased estrogenicity of a tamoxifen analog..Mol Endocrinol1995;9:1053-63

[65] Wolf DM.The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain..Breast Cancer Res Treat1994;31:129-38

[66] Merenbakh-Lamin K,Yeheskel A,Soussan-Gutman L.D538G mutation in estrogen receptor-alpha: a novel mechanism for acquired endocrine resistance in breast cancer..Cancer Res2013;73:6856-64

[67] Jeselsohn R,Buchwalter G,Meric-Bernstam F.Emergence of constitutively active estrogen receptor-alpha mutations in pretreated advanced estrogen receptor-positive breast cancer..Clin Cancer Res2014;20:1757-67 PMCID:PMC3998833

[68] Zhang QX,Wolf DM,Fuqua SA.An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer..Cancer research1997;57:1244-9

[69] Spoerke JM,Walter K,Wilson TR.Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant..Nat Commun2016;7:11579 PMCID:PMC4869259

[70] Arnold SF,Jaffe H.Phosphorylation of the human estrogen receptor on tyrosine 537 in vivo and by src family tyrosine kinases in vitro..Mol Endocrinol1995;9:24-33

[71] Jin K,Teo WW,Cho SS.HOXB7 is an ERα cofactor in the activation of HER2 and multiple ER target genes leading to endocrine resistance..Cancer Discov2015;5:944-59 PMCID:PMC4560624

[72] Miller TW,Gonzalez-Angulo AM,Mills GB.Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer..J Clin Invest2010;120:2406-13 PMCID:PMC2898598

[73] Lannigan DA.Estrogen receptor phosphorylation..Steroids2003;68:1-9

[74] Mao C,Kim JE.Antiestrogen resistant cell lines expressing estrogen receptor α mutations upregulate the unfolded protein response and are killed by BHPI..Sci Rep2016;6:34753 PMCID:PMC5054422

[75] Andruska ND,Yang X,Cherian MM.Estrogen receptor α inhibitor activates the unfolded protein response, blocks protein synthesis, and induces tumor regression..Proc Natl Acad Sci U S A2015;112:4737-42 PMCID:PMC4403155

[76] Zhao Y,Guillen VS,Min J.Structurally novel antiestrogens elicit differential responses from constitutively active mutant estrogen receptors in breast cancer cells and tumors..Cancer Res2017;77:5602-13 PMCID:PMC5645250

[77] Lai A,Govek S,Bonnefous C.Identification of GDC-0810 (ARN-810), an orally bioavailable selective estrogen receptor degrader (SERD) that demonstrates robust activity in tamoxifen-resistant breast cancer xenografts..J Med Chem2015;58:4888-904

[78] De Savi C,Rabow AA,de Almeida C.Optimization of a novel binding motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetra hydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a potent and orally bioavailable selective estrogen receptor downregulator and antagonist..J Med Chem2015;58:8128-40

[79] Mendelsohn ME.The protective effects of estrogen on the cardiovascular system..N Engl J Med1999;340:1801-11

[80] Torres MJ,Ryan TE,Lin CT.17β-Estradiol directly lowers mitochondrial membrane microviscosity and improves bioenergetic function in skeletal muscle..Cell Metab2018;27:167-79 PMCID:PMC5762397

[81] Gupte AA,Hamilton DJ.Estrogen: an emerging regulator of insulin action and mitochondrial function..J Diabetes Res2015;2015:916585 PMCID:PMC4391691

[82] Maniu A,Lynch TJ,Kim SO.Estrogen deprivation in primate pregnancy leads to insulin resistance in offspring..J Endocrinol2016;230:171-83 PMCID:PMC4946970

[83] Misso ML,Adams J,Murata Y.Differential expression of factors involved in fat metabolism with age and the menopause transition..Maturitas2005;51:299-306

[84] Ribas R,Gao Q,Rani A.Identification of chemokine receptors as potential modulators of endocrine resistance in oestrogen receptor-positive breast cancers..Breast Cancer Res2014;16:447 PMCID:PMC4303127

[85] Stender JD,Kastrati I,Strid T.Structural and molecular mechanisms of cytokine-mediated endocrine resistance in human breast cancer cells..Mol Cell2017;65:1122-35 PMCID:PMC5546241

[86] Du T,Levine KM,Riggins RB.Key regulators of lipid metabolism drive endocrine resistance in invasive lobular breast cancer..Breast Cancer Res2018;20:106 PMCID:PMC6124012

[87] Skildum A,Wallace K.Mitochondrial amplification selectively increases doxorubicin sensitivity in breast cancer cells with acquired antiestrogen resistance..Breast Cancer Res Treat2011;129:785-97

[88] Choi HK,Roh SH,Kang KW.Induction of multidrug resistance associated protein 2 in tamoxifen-resistant breast cancer cells..Endocr Relat Cancer2007;14:293-303

[89] Evans RM,Wang YX.PPARs and the complex journey to obesity..Nat Med2004;10:355-61

[90] Liao X,Lu Y,Sangwung P.Kruppel-like factor 4 is critical for transcriptional control of cardiac mitochondrial homeostasis..J Clin Invest2015;125:3461-76 PMCID:PMC4588311

[91] Weigt C,Kluxen FM,Hülsemann F.Molecular effects of ER alpha- and beta-selective agonists on regulation of energy homeostasis in obese female Wistar rats..Mol Cell Endocrinol2013;377:147-58

[92] Suzuki T,Miki Y,Moriya T.Peroxisome proliferator-activated receptor gamma in human breast carcinoma: a modulator of estrogenic actions..Endocr Relat Cancer2006;13:233-50

[93] Yin Y,Zeng X,Glazer RI.Inhibition of peroxisome proliferator-activated receptor gamma increases estrogen receptor-dependent tumor specification..Cancer Res2009;69:687-94 PMCID:PMC3693579

[94] Talbert DR,Zaytseva YY.Transactivation of ERalpha by rosiglitazone induces proliferation in breast cancer cells..Breast Cancer Res Treat2008;108:23-33

[95] Llopis J,Ricote M,Cho CY.Ligand-dependent interactions of coactivators steroid receptor coactivator-1 and peroxisome proliferator-activated receptor binding protein with nuclear hormone receptors can be imaged in live cells and are required for transcription..Proc Natl Acad Sci USA2000;97:4363-8 PMCID:PMC18247

[96] Ben-Neriah Y.Inflammation meets cancer, with NF-κB as the matchmaker..Nat Immunol2011;12:715-23

[97] Shah KN,Malla R,Faridi JS.Targeting ribonucleotide reductase M2 and NF-κB activation with Didox to circumvent tamoxifen resistance in breast cancer..Mol Cancer Ther2015;14:2411-21

[98] Zhou Y,Gray JW,Dairkee SH.Enhanced NF-κB and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer..BMC Cancer2007;14:59-74

[99] Baumgarten SC.Minireview: Inflammation: an instigator of more aggressive estrogen receptor (ER) positive breast cancers..Mol Endocrinol2012;26:360-71 PMCID:PMC3286192

[100] Zhu P,Bourk EM,Garcia-Bassets I.Macrophage/cancer cell interactions mediate hormone resistance by a nuclear receptor derepression pathway..Cell2006;124:615-29

[101] Sas L,Vermeulen PB,Van Dam P.The interaction between ER and NFκB in resistance to endocrine therapy..Breast Cancer Res2012;14:212 PMCID:PMC3680926

[102] De Bosscher K,Haegeman G.Cross-talk between nuclear receptors and nuclear factor kappaB..Oncogene2006;25:6868-86

[103] Cvoro A,Tatomer D,Fox MS.Distinct roles of unliganded and liganded estrogen receptors in transcriptional repression..Mol Cell2006;21:555-64

[104] Jiang C,Seed B.PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines..Nature1998;391:82-6

[105] Ricote M,Willson TM,Glass CK.The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation..Nature1998;391:79-82

[106] Soccio RE,Lazar MA.Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes..Cell Metab2014;20:573-91 PMCID:PMC4192012

[107] Sugii S,Sears DD,Atkins AR.PPARgamma activation in adipocytes is sufficient for systemic insulin sensitization..Proc Natl Acad Sci U S A2009;106:22504-9 PMCID:PMC2794650

[108] Franco HL,Kraus WL.TNFα signaling exposes latent estrogen receptor binding sites to alter the breast cancer cell transcriptome..Mol Cell2015;58:21-34 PMCID:PMC4385449

[109] Ross-Innes CS,Teschendorff AE,Ali HR.Differential oestrogen receptor binding is associated with clinical outcome in breast cancer..Nature2012;481:389-93 PMCID:PMC3272464

[110] Anderson GL,Aragaki AK,Manson JE.Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal hysterectomy: extended follow-up of the Women’s Health Initiative Randomised Trial..Lancet Oncol2012;13:476-86 PMCID:PMC3412626

[111] Sweeney EE,Jordan VC.Molecular modulation of estrogen-induced apoptosis by synthetic progestins in hormone replacement therapy: an insight into the women’s health initiative study..Cancer Res2014;74:7060-8 PMCID:PMC4254051

[112] Rhen T.Antiinflammatory action of glucocorticoids—new mechanisms for old drugs..N Engl J Med2005;353:1711-23

[113] De Bosscher K,Elewaut D.Targeting inflammation using selective glucocorticoid receptor modulators..Curr Opin Pharmacol2010;10:497-504

[114] Oh KS,Gottschalk RA,Baek S.Anti-inflammatory chromatinscape suggests alternative mechanisms of glucocorticoid receptor action..Immunity2017;47:298-309 PMCID:PMC5572836

[115] Vandevyver S,Van Bogaert T,Liu Y.Glucocorticoid receptor dimerization induces MKP1 to protect against TNF-induced inflammation..J Clin Invest2012;122:2130-40 PMCID:PMC3366401

[116] Miller WR.Molecular effects of oestrogen deprivation in breast cancer..Mol Cell Endocrinol2011;340:127-36

[117] Ariazi EA,Lewis-Wambi JS,Willis AL.Estrogen induces apoptosis in estrogen deprivation-resistant breast cancer through stress responses as identified by global gene expression across time..Proc Natl Acad Sci U S A2011;108:18879-86 PMCID:PMC3223472

[118] Fan P,Agboke FA,Zou X.c-Src modulates estrogen-induced stress and apoptosis in estrogen-deprived breast cancer cells..Cancer Res2013;73:4510-20 PMCID:PMC3715569

[119] Sweeney EE,Jordan VC.Mechanisms underlying differential response to estrogen-induced apoptosis in long-term estrogen-deprived breast cancer cells..Int J Oncol2014;44:1529-38 PMCID:PMC4144033

[120] Ferrara P,Bossis G,Brockly F.The structural determinants responsible for c-Fos protein proteasomal degradation differ according to the conditions of expression..Oncogene2003;22:1461-74

[121] Fan P,Abderrahman B,Yerrum S.Suppression of Nuclear Factor-κB by Glucocorticoid Receptor Blocks Estrogen-induced Apoptosis in Estrogen-deprived Breast Cancer Cells..Mol Cancer Ther. Forthcoming2019;

[122] Zhang K.From endoplasmic-reticulum stress to the inflammatory response..Nature2008;454:455-62 PMCID:PMC2727659

[123] Zaytseva YY,Southard RC,Kilgore MW.Down-regulation of PPARgamma1 suppresses cell growth and induces apoptosis in MCF-7 breast cancer cells..Mol Cancer2008;7:90 PMCID:PMC2614423

[124] Wang X,Wong J.PPARγ maintains ERBB2-positive breast cancer stem cells..Oncogene2013;32:5512-21 PMCID:PMC3898098

[125] Coussens LM,Palucka AK.Neutralizing tumor-promoting chronic inflammation: a magic bullet?.Science2013;339:286-91 PMCID:PMC3591506

[126] Weinberg F,Wheaton WW,Joseph J.Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity..Proc Natl Acad Sci USA2010;107:8788-93 PMCID:PMC2889315

[127] Hetz C,Harding HP.Targeting the unfolded protein response in disease..Nat Rev Drug Discov2013;12:703-19

[128] Maximov PY,Curpan RF,Fan P.A unifying biology of sex steroid-induced apoptosis in prostate and breast cancers..Endocr Relat Cancer2018;25:R83-113 PMCID:PMC5771961